Profile data is unavailable for this security.
About the company
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
- Revenue in USD (TTM)20.97m
- Net income in USD-118.51m
- Incorporated2004
- Employees55.00
- LocationCara Therapeutics Inc400 Atlantic Street, Suite 500STAMFORD 06901United StatesUSA
- Phone+1 (203) 406-3700
- Fax+1 (203) 567-1510
- Websitehttps://www.caratherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ImmuCell Corp | 17.47m | -5.77m | 39.36m | 79.00 | -- | 1.56 | -- | 2.25 | -0.7454 | -0.7454 | 2.26 | 3.22 | 0.3941 | 1.96 | 8.86 | 221,160.40 | -13.03 | -5.16 | -14.19 | -5.53 | 22.15 | 40.04 | -33.05 | -12.64 | 0.8715 | -15.17 | 0.3238 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
Lexaria Bioscience Corp | 404.72k | -5.44m | 40.33m | 5.00 | -- | 5.95 | -- | 99.65 | -0.6851 | -0.6851 | 0.0493 | 0.5264 | 0.0722 | -- | 1.64 | 80,944.00 | -97.62 | -95.67 | -94.18 | -96.58 | 95.66 | 76.98 | -1,351.64 | -1,612.76 | -- | -175.33 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
Bright Green Corp | 0.00 | -13.13m | 40.79m | 5.00 | -- | 3.61 | -- | -- | -0.0732 | -0.0732 | 0.00 | 0.0594 | 0.00 | -- | -- | 0.00 | -64.24 | -- | -97.68 | -- | -- | -- | -- | -- | -- | -5,488.51 | 0.0181 | -- | -- | -- | 52.54 | -- | -- | -- |
Aspira Women's Health Inc | 9.15m | -16.69m | 41.31m | 64.00 | -- | -- | -- | 4.51 | -1.73 | -1.73 | 0.9683 | -0.2222 | 0.7746 | 14.34 | 6.77 | 143,031.30 | -141.23 | -110.58 | -256.99 | -151.88 | 57.48 | 45.23 | -182.32 | -334.08 | 0.9871 | -- | -- | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
Dyadic International Inc | 2.90m | -6.80m | 41.81m | 7.00 | -- | 7.01 | -- | 14.42 | -0.2359 | -0.2359 | 0.1007 | 0.204 | 0.2643 | -- | 7.28 | 414,115.70 | -61.97 | -36.82 | -78.87 | -39.85 | 31.84 | 22.47 | -234.42 | -410.16 | -- | -- | 0.00 | -- | -1.07 | 17.48 | 30.20 | -- | -- | -- |
Bolt Biotherapeutics Inc | 7.88m | -69.20m | 41.94m | 100.00 | -- | 0.3719 | -- | 5.33 | -1.83 | -1.83 | 0.2083 | 2.96 | 0.0406 | -- | -- | 78,760.00 | -35.71 | -48.32 | -40.23 | -54.03 | -- | -- | -878.58 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
SensaSure Technologies Inc | 1.15k | -1.94m | 42.26m | 1.00 | -- | -- | -- | 36,749.47 | -0.0344 | -0.0344 | 0.00002 | -0.011 | 0.0336 | -- | -- | 1,150.00 | -5,689.09 | -- | -- | -- | -- | -- | -169,534.80 | -- | -- | -2.71 | -- | -- | -31.15 | -- | 17.62 | -- | -- | -- |
Carmell Corp | 0.00 | -16.88m | 42.34m | 9.00 | -- | 2.05 | -- | -- | -1.53 | -1.46 | 0.00 | 1.07 | -- | -- | -- | 0.00 | -- | -- | -- | -- | 58.60 | -- | -- | -- | -- | -194.46 | 0.0495 | -- | -- | -- | -75.70 | -- | -- | -- |
Cara Therapeutics Inc | 20.97m | -118.51m | 42.54m | 55.00 | -- | 0.7427 | -- | 2.03 | -2.19 | -2.19 | 0.3872 | 1.05 | 0.1361 | 2.37 | 6.96 | 381,236.40 | -76.94 | -35.76 | -91.50 | -40.82 | 70.56 | -- | -565.21 | -162.10 | 4.43 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
Quince Therapeutics Inc | 0.00 | -31.39m | 42.57m | 32.00 | -- | 0.4975 | -- | -- | -0.8424 | -0.8424 | 0.00 | 1.98 | 0.00 | -- | -- | 0.00 | -23.09 | -42.72 | -24.22 | -46.06 | -- | -- | -- | -- | -- | -- | 0.1363 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
NextCure Inc | 0.00 | -62.72m | 42.80m | 82.00 | -- | 0.3731 | -- | -- | -2.25 | -2.25 | 0.00 | 4.10 | 0.00 | -- | -- | 0.00 | -40.18 | -22.59 | -42.35 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
Cyclo Therapeutics Inc | 1.08m | -20.06m | 43.36m | 8.00 | -- | 9.06 | -- | 40.28 | -1.33 | -1.33 | 0.0679 | 0.1666 | 0.1233 | 0.387 | 12.14 | 134,551.30 | -229.72 | -132.22 | -727.50 | -215.17 | 90.85 | 90.37 | -1,863.35 | -1,114.04 | 1.42 | -2,769.34 | 0.00 | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
Xilio Therapeutics Inc | 0.00 | -76.40m | 43.56m | 73.00 | -- | 0.8846 | -- | -- | -2.78 | -2.78 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -76.37 | -- | -93.74 | -- | -- | -- | -- | -- | -- | -131.89 | 0.0826 | -- | -- | -- | 13.40 | -- | -- | -- |
Matinas BioPharma Holdings Inc | 1.10m | -22.94m | 43.87m | 32.00 | -- | 1.97 | -- | 40.03 | -0.1056 | -0.1056 | 0.005 | 0.0886 | 0.0314 | -- | -- | 34,250.00 | -65.62 | -44.62 | -72.81 | -48.25 | -- | -- | -2,093.25 | -2,344.60 | -- | -- | 0.0012 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
IN8BIO, Inc. | 0.00 | -30.01m | 44.02m | 31.00 | -- | 1.74 | -- | -- | -1.02 | -1.02 | 0.00 | 0.5761 | 0.00 | -- | -- | 0.00 | -89.91 | -74.18 | -108.07 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0466 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
Sensei Biotherapeutics Inc | 0.00 | -34.10m | 44.88m | 27.00 | -- | 0.6904 | -- | -- | -1.21 | -1.21 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -35.38 | -47.03 | -38.31 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0247 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Dec 2023 | 3.18m | 5.83% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 2.59m | 4.74% |
Disciplined Growth Investors, Inc.as of 31 Dec 2023 | 1.81m | 3.32% |
Chescapmanager LLCas of 31 Dec 2023 | 1.75m | 3.21% |
Farallon Capital Management LLCas of 31 Dec 2023 | 1.56m | 2.85% |
Rosalind Advisors, Inc.as of 31 Mar 2024 | 1.55m | 2.83% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.02m | 1.87% |
Geode Capital Management LLCas of 31 Dec 2023 | 1.01m | 1.85% |
Federated MDTA LLCas of 31 Dec 2023 | 831.85k | 1.52% |
AQR Capital Management LLCas of 31 Dec 2023 | 828.80k | 1.52% |